Soluble class I antigen secretion by peripheral blood lymphocytes in multiple sclerosis. 1993

J C Alvarez-Cermeño, and J A Brieva, and L M Villar, and E Roldán, and A Bootello, and P González-Porqué
Department of Neurology, Hospital Ramón y Cajal, Madrid, Spain.

We have quantified the soluble class I antigen (sHLA) secretion by peripheral blood lymphocytes of 26 multiple sclerosis (MS) patients. Thirteen of them were in a stable phase of the disease, 6 on relapse and 7 suffered from a progressive MS. sHLA secretion was reduced in the presence or absence of phytohemagglutinin in patients with either active or stable MS, being normal after stimulation with a monoclonal antibody anti-CD3. In MS patients, lymphocyte proliferation and immunoglobulin secretion were found to be similar to those of 29 healthy blood donors who comprised the group of controls. These results reflect systemic anomalies in the cell activation process in MS, which seem to be independent of the disease activity. Whether these alterations are specific to MS or are common to other inflammatory CNS diseases remains to be elucidated.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004185 Disability Evaluation Determination of the degree of a physical, mental, or emotional handicap. The diagnosis is applied to legal qualification for benefits and income under disability insurance and to eligibility for Social Security and workmen's compensation benefits. Disability Evaluations,Evaluation, Disability,Evaluations, Disability
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015395 Histocompatibility Antigens Class I Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells. Class I Antigen,Class I Antigens,Class I Histocompatibility Antigen,Class I MHC Protein,Class I Major Histocompatibility Antigen,MHC Class I Molecule,MHC-I Peptide,Class I Histocompatibility Antigens,Class I Human Antigens,Class I MHC Proteins,Class I Major Histocompatibility Antigens,Class I Major Histocompatibility Molecules,Human Class I Antigens,MHC Class I Molecules,MHC-I Molecules,MHC-I Peptides,Antigen, Class I,Antigens, Class I,I Antigen, Class,MHC I Molecules,MHC I Peptide,MHC I Peptides,Molecules, MHC-I,Peptide, MHC-I,Peptides, MHC-I

Related Publications

J C Alvarez-Cermeño, and J A Brieva, and L M Villar, and E Roldán, and A Bootello, and P González-Porqué
March 2003, Burns : journal of the International Society for Burn Injuries,
J C Alvarez-Cermeño, and J A Brieva, and L M Villar, and E Roldán, and A Bootello, and P González-Porqué
January 1992, Journal of neuroimmunology,
J C Alvarez-Cermeño, and J A Brieva, and L M Villar, and E Roldán, and A Bootello, and P González-Porqué
October 1985, Journal of neuroimmunology,
J C Alvarez-Cermeño, and J A Brieva, and L M Villar, and E Roldán, and A Bootello, and P González-Porqué
March 1998, Tissue antigens,
J C Alvarez-Cermeño, and J A Brieva, and L M Villar, and E Roldán, and A Bootello, and P González-Porqué
September 1990, The Journal of clinical investigation,
J C Alvarez-Cermeño, and J A Brieva, and L M Villar, and E Roldán, and A Bootello, and P González-Porqué
March 2002, Journal of neuroimmunology,
J C Alvarez-Cermeño, and J A Brieva, and L M Villar, and E Roldán, and A Bootello, and P González-Porqué
January 1989, Annual review of immunology,
J C Alvarez-Cermeño, and J A Brieva, and L M Villar, and E Roldán, and A Bootello, and P González-Porqué
November 2006, International journal of radiation biology,
J C Alvarez-Cermeño, and J A Brieva, and L M Villar, and E Roldán, and A Bootello, and P González-Porqué
October 1989, Transplantation,
J C Alvarez-Cermeño, and J A Brieva, and L M Villar, and E Roldán, and A Bootello, and P González-Porqué
November 1979, Annals of neurology,
Copied contents to your clipboard!